Webinar Access: 5 Myths About Obesity and the New Weight Loss Drugs
Prescription weight loss medications, such as GLP-1 agonists, have shown promising results in treating obesity and cardiovascular disease. In a recent On the Pulse webinar from the Minneapolis Heart Institute Foundation, Dr. Michael Miedema, Director of the Nolan Family Center for Cardiovascular Health, addressed common misunderstandings about GLP-1 medications, shared some good news, and confirmed these drugs are not a substitute for time-tested approaches to treating overweight/obesity and heart disease.
About Minneapolis Heart Institute Foundation
The Minneapolis Heart Institute Foundation (MHIF) strives to create a world without heart and vascular disease. For over 40 years, MHIF has been one of the leading nonprofit cardiovascular and vascular research and education institutions in the country with over 230 active research studies and publications ongoing each year.
We partner with 100+ cardiologists at Allina Health Minneapolis Heart Institute (AHMHI), which has been one of the top-rated cardiovascular care centers in the world since 1981 and consistently is awarded with national rankings by US News and World Report for cardiology and heart surgery. Our integration with this high-quality, high-volume cardiovascular care center at Abbott Northwestern Hospital allows us to study and offer cutting-edge treatment to a large number of patients.
